CA3181333A1 — Crystals, preparation method and application of a muscarinic receptor antagonist

USPTO Abstract

The main purpose of the present invention is to provide a novel crystal of a quaternary ammonium salt structure compound, i.e., (2R,3R)-3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-(3-phenoxypropyl)-1-azabicyclo[2,2,2]octylonium bromide (hereinafter referred to as compound I). A type A crystal of compound I displays diffraction peaks at the following diffraction angles 2? in a powder X-ray diffraction pattern thereof: 5.7±0.2 degrees, 12.9±0.2 degrees, 16.7±0.2 degrees, 18.0±0.2 degrees, 19.5±0.2 degrees, 21.1±0.2 degrees, 22.3±0.2 degrees and 23.3±0.2 degrees. A type B crystal of compound I displays diffraction peaks at the following diffraction angles 2? in a powder X-ray diffraction pattern thereof: 5.2±0.2 degrees, 15.8±0.2 degrees, 16.9±0.2 degrees, 17.7±0.2 degrees, 19.5±0.2 degrees, 20.2±0.2 degrees and 22.1±0.2 degrees. The present invention also relates to a new preparation method for compound I and an application of the two novel crystals in the field of medicine.